Personalized Triple Therapy Shows 87.6% Response Rate in Advanced, Refractory Cancers

At a Houston oncology center, seventy-three patients whose cancers had outlasted every standard treatment were offered something medicine rarely provides: a therapy built not for their diagnosis, but for their tumor. The ICTriplex protocol—weaving chemotherapy, immunotherapy, and targeted agents into a plan shaped by each cancer's own genetic fingerprint—achieved remission in nearly nine of ten patients, and left four once-terminal individuals alive and disease-free five years later. The results, still early and drawn from a single center, nonetheless ask a quiet but consequential question: if